Pyrrolopyridines as kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9969727-B2
Application number	US-201614988521-A
Country	US
Kind code	B2
Filing date	Jan 5, 2016
Priority date	May 13, 2008
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

First claim

What is claimed is:

1. A compound of Formula:

or a stereoisomer, tautomer or salt thereof, wherein:
each PG is independently a protecting group selected from t-butyloxycarbonyl (BOC), 9-fluorenylmethyleneoxycarbonyl (Fmoc), and benzyloxycarbonyl (Cbz);
A is selected from a direct bond or CR a R b ;
each R 1a is independently halogen or OH;
R 1c is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl or a 5 or 6 membered heteroaryl, wherein the alkyl, cycloalkyl, phenyl or heteroaryl are optionally substituted with one or more groups selected from halogen, CN, CF 3 , C 1 -C 3 alkyl, —O(C 1 -C 3 alkyl) and NR c R d ;
R 1d is hydrogen or —S(C 1 -C 6 alkyl);
R 2 is selected from C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl), —NH(C 1 -C 6 alkyl), a saturated or partially unsaturated C 3 -C 6 cycloalkyl, phenyl, a saturated or partially unsaturated 4 to 6 membered heterocyclic, a 5 or 6 membered heteroaryl, an 8 to 10 membered bicyclic aryl, an 8 to 10 membered bicyclic heterocyclic, and an 8 to 10 membered bicyclic heteroaryl, wherein the alkyls, cycloalkyl, phenyl, heterocyclics, heteroaryls and aryl are optionally substituted with one or more groups selected from OH, CN, halogen, oxo (except not on phenyl, aryl or heteroaryl), CF 3 , cyclopropyl, cyclopropylmethyl, —SO 2 R i , C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl), —S(C 1 -C 6 alkyl), NR e R f , and phenyl, wherein the phenyl is optionally substituted with one or more groups selected from OH, CN, halogen, CF 3 , C 1 -C 3 alkyl, —O(C 1 -C 3 alkyl), and NR g R h ;
R 3 is selected from hydrogen and C 1 -C 4 alkyl optionally substituted with OH, F, —O(C 1 -C 3 alkyl) or C 3 -C 6 cycloalkyl;
R 5 is selected from hydrogen and CH 3 , or
A is CR a R b , R a and R b are hydrogen, and R 3 and R 5 together with the atoms to which they are attached form a 5 or 6 membered ring;
R 6 is selected from hydrogen, F, OH, —OCH 3 , C 1 -C 3 alkyl and cyclopropyl, or
A is a direct bond, R 6a is hydrogen and R 3 and R 6 together with the atoms to which they are attached form a 5 or 6 membered ring;
R 6a is selected from hydrogen, F, OH, and CH 3 ;
R 7 is hydrogen, or
A is CR a R b and R 3 and R 7 together with the atoms to which they are attached form a 5 or 6 membered ring;
R a is hydrogen, or
R b is absent and R 3 and R a together with the atoms to which they are attached form an aromatic 5 or 6 membered ring;
R b is hydrogen or absent;
R c and R d are independently selected hydrogen and C 1 -C 3 alkyl, or
R c and R d together with the atom to which they are attached form a 5 or 6 membered ring;
R e and R f are independently selected hydrogen and C 1 -C 3 alkyl;
R g and R h are independently selected from hydrogen and C 1 -C 3 alkyl;
R i is C 1 -C 3 alkyl; and
p is 2.

2. The compound of claim 1 , wherein R 2 is selected from C 1 -C 6 alkyl, a saturated or partially unsaturated C 3 -C 6 cycloalkyl, phenyl, a saturated or partially unsaturated 5 or 6 membered heterocyclic, a 5 or 6 membered heteroaryl, an 8 to 10 membered bicyclic aryl, an 8 to 10 membered bicyclic heterocyclic, and an 8 to 10 membered bicyclic heteroaryl, wherein the alkyl, cycloalkyl, phenyl, heterocyclic, heteroaryl and aryl are optionally substituted with one or more groups selected from OH, CN, halogen, oxo (except not on phenyl, aryl or heteroaryl), CF 3 , C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl), —S(C 1 -C 6 alkyl), and NR e R f .

3. The compound of claim 1 , wherein R 2 is selected from C 1 -C 6 alkyl, saturated C 3 -C 6 cycloalkyl, phenyl, saturated or partially unsaturated 5 or 6 membered heterocyclic, a 5 or 6 membered heteroaryl, and an 8 to 10 membered bicyclic heteroaryl, wherein the alkyl, cycloalkyl, phenyl, heterocyclic and heteroaryl are optionally substituted with halogen, oxo (except not on phenyl or heteroaryl), CF 3 , C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl) or C 3 -C 6 cycloalkyl.

4. The compound of claim 1 , wherein R 2 is selected from isopropyl, tert-butyl, isobutyl, cyclopropylmethyl, —CH(CH 2 CH 3 ) 2 , —CH 2 OCH 3 , —CH(CH 3 )OCH 3 , —CH 2 CH 2 OCH 3 , cyclopropyl, cyclobutyl, cyclopentyl, phenyl, 3-methylphenyl, 4-fluorophenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chloro-4-fluorophenyl, 3-fluoro-4-methoxyphenyl, 3-trifluoromethylphenyl, 2-fluoro-5-methylphenyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridazin-3 -yl, morpholin-2-yl, pyrazol-4-yl, 1-methyl-1H-pyrazol-3-yl, 2-methyloxazol-4-yl, 5-methylisoxazol-3-yl, 2-methylthiazol-4-yl, pyridin-2-yl, pyridin-3-yl, 6-methoxy-pyridin-2-yl, 3 -methylpyridin-2-yl, 5-chloro-pyridin-2-yl, 5-methylpyridin-2-yl, 2-methylpyridin-3 -yl, 5-methylpyridin-3 -yl, 5-chloropyridin-3-yl, 6-methylpyridin-3 -yl, pyrimidin-2-yl, pyrazin-2-yl, 5-methylpyrazin-2-yl and quinoxalin-2-yl.

5. The compound of claim 1 , wherein R 2 is selected from methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, cyclopropylmethyl, —CH 2 CF 3 , —CH(CH 2 CH 3 ) 2 , —CH 2 OH, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —CH(CH 3 )OCH 3 , —CH 2 CH 2 OCH 3 , —CH(CH 3 )OH, —C(CH 3 ) 2 OH, —CH 2 CN, —CH 2 CH 2 F, —C(CH 3 ) 2 F, —CH(CH 3 )CH 2 CH 3 , —CH 2 OCH(CH 3 ) 2 , —CH(CH 3 )OCH(CH 3 ) 2 , —CH 2 SO 2 CH 3 , —CH(CH 3 )phenyl, —CH 2 (phenyl), —OCH 2 CH 3 , —NH(CH 2 CH 3 ), cyclopropyl, cyclobutyl, cyclopentyl, 1-(trifluoromethyl)cyclopropyl, 1-(methoxy)cyclopropyl, 2,2-difluorocyclopropyl, 1-methylcyclopropyl, 2-phenylcyclopropyl, 2,2-dimethylcyclopropyl, phenyl, 3-methylphenyl, 4-fluorophenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chloro-4-fluorophenyl, 3-fluoro-4-methoxyphenyl, 3-trifluoromethylphenyl, 2-fluoro-5-methylphenyl, 3-methyloxetan-3-yl, azetidin-1-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl, 1-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl, 1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridazin-3-yl, morpholin-2-yl, pyrrolidin-1-yl, 5 -oxopyrrolidin-2-yl, pyrazol-4-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol -4-yl, 2-methyloxazol-4-yl, 5-methylisoxazol-3-yl, 2-methylthiazol-4-yl, pyridin-2-yl, pyridin-3-yl, 6-methoxy-pyridin-2-yl, 3-methylpyridin-2-yl, 5-chloro-pyridin-2-yl, 5-trifluoromethylpyridin-2-yl, 2-methylpyridin-3-yl, 5-methylpyridin-3-yl, 5-chloropyridin-3-yl, 6-methylpyridin-3-yl, pyrimidin-2-yl, 5-ethylpyrimidin-2-yl, pyrazin-2-yl, 5-methylpyrazin-2-yl, and quinoxalin-2-yl.

6. The compound of claim 1 , wherein A is a direct bond.

7. The compound of claim 1 , wherein A is CR a R b .

8. The compound of claim 1 , wherein R 3 is selected from hydrogen or C 1 -C 4 alkyl optionally substituted with OH, F or C 3 -C 6 cycloalkyl.

9. The compound of claim 1 , wherein R 3 is selected from hydrogen, methyl, isopropyl, isobutyl, CH 2 CH 2 OH and cyclopropylmethyl.

10. The compound of claim 1 , wherein R 3 is selected from hydrogen, methyl, ethyl, isopropyl, isobutyl, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , CH 2 CH 2 F and cyclopropylmethyl.

11. The compound of claim 1 , wherein R 5 is selected from hydrogen and CH 3 .

12. The compound of claim 1 , wherein A is CR a R b , R a and R b are hydrogen, and R 3 and R 5 together with the atoms to which they are attached form a 5 or 6 membered ring.

13. The compound of claim 1 , wherein R 6 is selected from hydrogen, F, OH, —OCH 3 and C 1 -C 3 alkyl.

14. The compound of claim 1 , wherein R 6 is hydrogen.

15. The compound of claim 1 , wherein A is a

Assignees

• Array Biopharma Inc

Inventors

• Le Huerou Yvan
• Blake James F
• Gunawardana Indrani W
• Mohr Peter J
• Wallace Eli M
• Wang Bin
• Chicarelli Mark Joseph
• Lyon Michael

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/06

  Antimigraine agents · CPC title